Search results
PROMOTED
Stay up to date with the latest clinical evidence in transthyretin amyloid cardiomyopathy (ATTR-CM) with this video series spotlighting key cardiomyopathy updates presented at ESC Heart Failure Congress (HFA) 2026.In the first session, Dr Mathew Maurer (Columbia University, New York, US) takes a deep dive into the CARDIO-TTRansform data, exploring the current treatment landscape and ongoing unmet…
View more
Spotlight on HFA 2026: Updates on Cardiomyopathies
Added:
1 month ago
Video Series
Added:
7 months ago
Stay at the forefront of cardiovascular medicine with our comprehensive video collection from the American Heart Association's Scientific Sessions 2025. Access expert analysis of the most impactful late-breaking trials and featured science shaping clinical practice.Late-Breaker Discussions: Watch Dr Harriette Van Spall break down pivotal clinical trial data and explore its implications for…
View more
Added:
1 year ago
Keep up-to-date with our video collection covering the American Heart Association's 2024 Scientific Sessions in Chicago. For expert insights on the hottest late-breaking and featured science trials, tune in to our collection.To catch reviews on the most awaited trials, watch our recurring series View From the ThoraxCenter, hosted by Prof Nicolas Van Mieghem andDr Joost Daemen (Thoraxcenter,…
View more
Added:
7 months ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Prof Stephen Nicholls (Monash University, AU) to present the findings of this AHA late-breaking trial.This pre-specified analysis of the SURPASS-CVOT randomised clinical trial evaluates the comparative effects of once-weekly tirzepatide versus dulaglutide on heart failure outcomes in…
View more
Added:
7 months ago
AHA Scientific Sessions 2025 – Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) presents results from the POLY-HF trial (NCT04633005), evaluating a polypill strategy combining multiple evidence-based medications for heart failure with reduced ejection fraction.This single-center randomized trial enrolled 212 patients with HFrEF (ejection fraction ≤40%) who were not…
View more
Added:
7 months ago
AHA Scientific Sessions 2025 – Dr Ambarish Pandey (University of Texas Southwestern Medical Center, US) presents findings from a randomized clinical trial comparing medically tailored meals versus produce supplements on heart failure readmissions and emergency department visits.The study was conducted across two centers in Dallas, Texas. Patients were randomized within two weeks following heart…
View more
Added:
1 year ago
AHA Conference 2024 - Discover the findings from a new study on the impact of diastolic dysfunction on the efficacy of empagliflozin in heart failure in the EMPEROR-Preserved trial.Prof Andrew Coats (Heart Research Institute, New South Wales, AU) joins us onsite at AHA Conference to discuss findings from a new analysis of diastolic dysfunction in the EMPEROR-Preserved trial (NCT03057951).EMPEROR…
View more
Added:
7 months ago
AHA Scientific Sessions 2025 – MAPLE-HCM responder analysis shows aficamten monotherapy led to greater treatment effect when compared to metoprolol monotherapy.Dr Andrew Wang (Duke University Medical Center, Durham, NC, US) presents a responder analysis from the MAPLE-HCM trial (NCT05767346), examining clinical responses to aficamten monotherapy versus metoprolol in patients with obstructive…
View more
Added:
7 months ago
AHA Scientific Sessions 2025 - Dr Milton Packer (Baylor University Medical Center, US) joins us to discuss his novel unifying hypothesis that heart failure with preserved ejection fraction arises primarily from visceral adipose tissue dysfunction and altered adipokine signaling, rather than as a heterogeneous disorder driven by multiple comorbidities.Interview Questions:Can you explain the core…
View more
Added:
7 months ago
AHA Scientific Sessions 2025 - Prof Nobuyuki Kagiyama (Juntendo University School of Medicine, Tokyo, JP) joins us to share findings from the AI-SCREEN-CA study investigating whether an artificial intelligence-based software for checking real-world echocardiography can improve the early and accurate detection of hidden cardiac amyloidosis.Findings showed that this AI software identified around 5%…
View more